A Phase 2 interventional study of Placebo and ATX-101 (1 mg/cm^2) in Submental Fat and Healthy, sponsored by Kythera Biopharmaceuticals. Completed at 20 sites in 4 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-17.
Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a long-term follow-up study of participants who completed Kythera-sponsored trials of ATX-101 (06-03, 07-07, 09-15)
No study medication was administered in this study.
Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
First submitted before Kythera Biopharmaceuticals became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants treated with placebo in previous ATX-101 studies
Drug: Placebo
Participants treated with ATX-101 (1 mg/cm\^2) in previous phase 2 studies
Drug: ATX-101 (1 mg/cm^2)
Participants treated with ATX-101 (2 mg/cm\^2) in previous phase 2 studies
Drug: ATX-101 (2 mg/cm^2)
Participants treated with ATX-101 (4 mg/cm\^2) in previous phase 2 studies
Drug: ATX-101 (4 mg/cm^2)
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Drug page: APIM-containing Peptide ATX-101
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Drug page: APIM-containing Peptide ATX-101
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Drug page: APIM-containing Peptide ATX-101
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)
Percentage of Participants Maintaining PR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)
Percentage of Participants Maintaining Composite SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)
Percentage of Participants Maintaining Composite SMFRS 2-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)
The objective of this non-treatment, placebo-controlled, 5-year follow-up study was to evaluate the long-term efficacy and safety of subcutaneous (SC) injections of deoxycholic acid (ATX-101) in the submental area. No treatment was administered in this study.
| Milestone | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Started | 140 | 65 |
| Completed | 98 | 44 |
| Not completed | 42 | 21 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Subject's request | 13 | 10 |
| Withdrew: Lost to follow-up | 24 | 9 |
| Withdrew: Non compliance | 2 | 0 |
| Withdrew: Other unspecified | 3 | 1 |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Baseline | 100.0 | 100.0 |
| Visit 1 (Month 3) | 93.1 | 83.3 |
| Visit 2 (Month 6) | 94.0 | 68.8 |
| Visit 3 (Month 9) | 94.9 | 81.3 |
| Visit 4 (Month 12) | 94.0 | 82.4 |
| Visit 5 (Month 18) | 95.1 | 83.3 |
| Visit 6 (Month 24) | 89.6 | 75.0 |
| Visit 7 (Month 36) | 80.8 | 76.5 |
| Visit 8 (Month 48) | 85.2 | 64.3 |
| Visit 9 (Month 60) | 71.2 | 71.4 |
The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Baseline | 100.0 | 100.0 |
| Visit 1 (Month 3) | 94.7 | 73.3 |
| Visit 2 (Month 6) | 94.1 | 80.0 |
| Visit 3 (Month 9) | 87.5 | 94.4 |
| Visit 4 (Month 12) | 85.0 | 94.4 |
| Visit 5 (Month 18) | 80.6 | 83.3 |
| Visit 6 (Month 24) | 85.7 | 82.4 |
| Visit 7 (Month 36) | 81.8 | 94.1 |
| Visit 8 (Month 48) | 78.1 | 80.0 |
| Visit 9 (Month 60) | 84.8 | 93.3 |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Baseline | 100.0 | 100.0 |
| Visit 1 (Month 3) | 84.6 | 75.0 |
| Visit 2 (Month 6) | 82.6 | 83.3 |
| Visit 3 (Month 9) | 82.8 | 100.0 |
| Visit 4 (Month 12) | 79.3 | 71.4 |
| Visit 5 (Month 18) | 73.1 | 71.4 |
| Visit 6 (Month 24) | 73.1 | 83.3 |
| Visit 7 (Month 36) | 65.2 | 85.7 |
| Visit 8 (Month 48) | 60.9 | 83.3 |
| Visit 9 (Month 60) | 73.9 | 83.3 |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Baseline | 100.0 | 100.0 |
| Visit 1 (Month 3) | 0.0 | 0.0 |
| Visit 2 (Month 6) | 66.7 | 100.0 |
| Visit 3 (Month 9) | 66.7 | 100.0 |
| Visit 4 (Month 12) | 100.0 | 100.0 |
| Visit 5 (Month 18) | 0.0 | 100.0 |
| Visit 6 (Month 24) | 100.0 | 100.0 |
| Visit 7 (Month 36) | 100.0 | 0.0 |
| Visit 8 (Month 48) | 100.0 | 0.0 |
| Visit 9 (Month 60) | 100.0 | 100.0 |
Collected over Up to 60 months from the last visit in the previous study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATX-101 (Deoxycholic Acid) Injection | 0/140 (0%) | 3/140 (2.1%) | 0/140 (0%) |
| Placebo | 1/65 (1.5%) | 3/65 (4.6%) | 0/65 (0%) |
| Event | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Patient died of pancreatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/140 | 1/65 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/140 | 1/65 |
| HypocalcemiaMetabolism and nutrition disorders | 0/140 | 1/65 |
| Thyroid cancerEndocrine disorders | 0/140 | 1/65 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/140 | 0/65 |
| Asymptomatic cystic thyroid massEndocrine disorders | 1/140 | 0/65 |
| Third degree heart blockCardiac disorders | 1/140 | 0/65 |
| Age, Continuous(Years) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Mean | 46.8 ± 8.86 | 48.2 ± 9.94 | 47.2 ± 9.22 |
| Sex: Female, Male(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Female | 111 | 43 | 154 |
| Male | 29 | 22 | 51 |
| Race (NIH/OMB)(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 131 | 56 | 187 |
| More than one race | 7 | 5 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline weight (kg)(kilogram (kg)) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Mean | 80.64 ± 16.683 | 85.93 ± 15.983 | 82.32 ± 16.610 |
The record gives a start of Feb 2009, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2020, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: APIM-containing Peptide ATX-101